for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Sosei Group unit says first subject dosed in Phase1 clinical study of novel selective muscarinic M4 agonist in development to treat major symptoms of Alzheimer's disease

Sept 1 (Reuters) - Sosei Group Corp

* Says co’s unit Heptares Therapeutics and Allergan announced that the first healthy subject has been dosed with the first-in-class, selective muscarinic M4 receptor agonist HTL0016878 in a Phase 1 clinical study

* Says unit will receive $15 million milestone payment under a global R&D and commercialisation partnership announced in April 2016

Source text in Japanese: goo.gl/GiYgfQ

Further company coverage: (Beijing Headline News)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up